Hydroxyprogesterones: Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.Progestins: Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.17-alpha-Hydroxyprogesterone: A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. It serves as an intermediate in the biosynthesis of HYDROCORTISONE and GONADAL STEROID HORMONES.Premature Birth: CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).Obstetric Labor, Premature: Onset of OBSTETRIC LABOR before term (TERM BIRTH) but usually after the FETUS has become viable. In humans, it occurs sometime during the 29th through 38th week of PREGNANCY. TOCOLYSIS inhibits premature labor and can prevent the BIRTH of premature infants (INFANT, PREMATURE).Adrenal Hyperplasia, Congenital: A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.17-alpha-Hydroxypregnenolone: A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. It is an intermediate in the delta-5 pathway of biosynthesis of GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Steroid 21-Hydroxylase: An adrenal microsomal cytochrome P450 enzyme that catalyzes the 21-hydroxylation of steroids in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP21 gene, converts progesterones to precursors of adrenal steroid hormones (CORTICOSTERONE; HYDROCORTISONE). Defects in CYP21 cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL).Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.Gestational Age: The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated as the time from the last day of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization.Infant, Premature: A human infant born before 37 weeks of GESTATION.Infant, Newborn: An infant during the first month after birth.Pregnancy, Twin: The condition of carrying TWINS simultaneously.Pregnanetriol: A metabolite of 17-ALPHA-HYDROXYPROGESTERONE, normally produced in small quantities by the GONADS and the ADRENAL GLANDS, found in URINE. An elevated urinary pregnanetriol is associated with CONGENITAL ADRENAL HYPERPLASIA with a deficiency of STEROID 21-HYDROXYLASE.Pregnancy Outcome: Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; SPONTANEOUS ABORTION; INDUCED ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.Pregnanes: Saturated derivatives of the steroid pregnane. The 5-beta series includes PROGESTERONE and related hormones; the 5-alpha series includes forms generally excreted in the urine.Chorioamnionitis: INFLAMMATION of the placental membranes (CHORION; AMNION) and connected tissues such as fetal BLOOD VESSELS and UMBILICAL CORD. It is often associated with intrauterine ascending infections during PREGNANCY.Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.17-Ketosteroids: Steroids that contain a ketone group at position 17.Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.Adrenocortical Hyperfunction: Excess production of ADRENAL CORTEX HORMONES such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and/or ANDROSTENEDIONE. Hyperadrenal syndromes include CUSHING SYNDROME; HYPERALDOSTERONISM; and VIRILISM.Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.Fetal Membranes, Premature Rupture: Spontaneous tearing of the membranes surrounding the FETUS any time before the onset of OBSTETRIC LABOR. Preterm PROM is membrane rupture before 37 weeks of GESTATION.Infant, Low Birth Weight: An infant having a birth weight of 2500 gm. (5.5 lb.) or less but INFANT, VERY LOW BIRTH WEIGHT is available for infants having a birth weight of 1500 grams (3.3 lb.) or less.Nafarelin: A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.Hydrocortisone: The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.Clitoris: An erectile structure homologous with the penis, situated beneath the anterior labial commissure, partially hidden between the anterior ends of the labia minora.Adrenocorticotropic Hormone: An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).Pregnancy, Triplet: The condition of carrying TRIPLETS simultaneously.Pregnancy Trimester, Second: The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation.Delivery, Obstetric: Delivery of the FETUS and PLACENTA under the care of an obstetrician or a health worker. Obstetric deliveries may involve physical, psychological, medical, or surgical interventions.Pregnancy Complications: Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.Steroid 17-alpha-Hydroxylase: A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation.Testosterone: A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.Progesterone: The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.Cervical Ripening: A change in the CERVIX UTERI with respect to its readiness to relax. The cervix normally becomes softer, more flexible, more distensible, and shorter in the final weeks of PREGNANCY. These cervical changes can also be chemically induced (LABOR, INDUCED).Pregnenolone: A 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.Drug Delivery Systems: Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.Cervix Uteri: The neck portion of the UTERUS between the lower isthmus and the VAGINA forming the cervical canal.Pregnancy Trimester, Third: The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation.Amniotic Fluid: A clear, yellowish liquid that envelopes the FETUS inside the sac of AMNION. In the first trimester, it is likely a transudate of maternal or fetal plasma. In the second trimester, amniotic fluid derives primarily from fetal lung and kidney. Cells or substances in this fluid can be removed for prenatal diagnostic tests (AMNIOCENTESIS).Androgens: Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.Uterine Cervical Incompetence: Incompetent UTERINE CERVIX is usually diagnosed in the second trimester of PREGNANCY. It is characterized by passive painless cervical dilation in the absence of UTERINE CONTRACTION; BLEEDING; INFECTION; and sometimes with the amniotic sac (AMNIOTIC MEMBRANE) bulging through the partially dilated cervix. Left untreated, this condition may lead to premature pregnancy loss, such as HABITUAL ABORTION.Cosyntropin: A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.Tocolysis: Any drug treatment modality designed to inhibit UTERINE CONTRACTION. It is used in pregnant women to arrest PREMATURE LABOR.Adrenal Glands: A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.Infant, Small for Gestational Age: An infant having a birth weight lower than expected for its gestational age.Infant, Premature, DiseasesPregnancy Complications, Infectious: The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION.Puberty, Precocious: Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.
2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy. OHPC is ... The use of OHPC in pregnancy to prevent preterm birth in women with a history of preterm delivery between 20 weeks and 36 weeks ... 2003). "Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate". N Engl J Med. 348 (24): 2379-85. ... Hydroxyprogesterone caproate is the generic name of OHPC and its INN, USAN, BANM, and JAN, while hydroxyprogesterone hexanoate ...
Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery. J Perinat Med. ... often given in the form of progesterone or hydroxyprogesterone caproate, relaxes the uterine musculature, maintains cervical ... It is estimated that one-third of these low birth weight deliveries are due to preterm delivery. Weight generally correlates to ... Preterm birth causes a range of problems. The main categories of causes of preterm birth are preterm labor induction and ...
... hydroxyprogesterone caproate injection, alpha hydroxyprogesterone caproate, 17 alpha hydroxyprogesterone, massachusetts ... 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy. ... 17alpha-Hydroxyprogesterone caproate; Hydroxy progesterone caproate; (8xi,10xi,13xi)-3,20-dioxopregn-4- en-17-yl hexanoate; 3, ... Hot Tags: hydroxyprogesterone hydroxyprogesterone caproate injection alpha hydroxyprogesterone caproate 17 alpha ...
Delivery before 35 weeks of gestation, Delivery before 32 weeks of gestation, Admission during current pregnancy for preterm ... Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate. The safety and scientific validity ... Preterm Delivery Drug: 17-alpha Hydroxyprogesterone Caproate Drug: Castor oil Phase 2 ... Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate. ...
Hydroxyprogesterone Caproate reference guide for safe and effective use from the American Society of Health-System Pharmacists ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003; 348:2379-85. http://www. ... The effect of esterases on 17alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2008; 198:229.e1-5. ... Uses for Hydroxyprogesterone Caproate. Preterm Birth Risk Reduction. Reduction of risk of preterm birth in women with a ...
11-hydroxyprogesterone. Hormones. Hormones, Hormone Substitutes, and Hormone Antagonists. Physiological Effects of Drugs. ... 0.80 and alpha = 0.025 study needs to enrol 160 patients/arm, with a total of 480 patients. ... Main outcome: Delivery before 37 weeks.. Secondary outcomes: Gestational age at delivery, Delivery ,32, ,35 wks, hospital ... Progestagens for the Tertiary Prophylaxis of Preterm Delivery (PROTECT). The safety and scientific validity of this study is ...
2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy. OHPC is ... The use of OHPC in pregnancy to prevent preterm birth in women with a history of preterm delivery between 20 weeks and 36 weeks ... 2003). "Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate". N Engl J Med. 348 (24): 2379-85. ... Hydroxyprogesterone caproate is the generic name of OHPC and its INN, USAN, BANM, and JAN, while hydroxyprogesterone hexanoate ...
... gestation are indicative of active preterm labor. If the diagnosis ... more ... Perinatal morbidity associated with late preterm deliveries compared with deliveries between 37 and 40 weeks of gestation. BJOG ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12. 348(24):2379-85. ... Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016 Apr 7. 374 (14):1311-20. [Medline]. ...
The exact mechanisms of preterm labor are largely unknown but are believed to include the following: Decidual hemorrhage such ... Perinatal morbidity associated with late preterm deliveries compared with deliveries between 37 and 40 weeks of gestation. BJOG ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12. 348(24):2379-85. ... Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016 Apr 7. 374 (14):1311-20. [Medline]. ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N. Engl. J. Med. 2003, 348, 2379-2385. [ ... splicing and glucocorticoid-induced expression of cardiac alpha 1C and alpha 1D voltage-gated Ca2+ channel mRNAs. J. Mol. Cell ... Haas, D.M.; Caldwell, D.M.; Kirkpatrick, P.; McIntosh, J.J.; Welton, N.J. Tocolytic therapy for preterm delivery: Systematic ... Nikolov, A.; Markov, D.; Dimitrov, A.; Ivanov, S.; Diavolov, V. Treatment of preterm delivery with calcium channel blockers- ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12;348(24):2379-85. ... Hydroxyprogesterone 17-. Reprotox. org. March 1, 2003. Florey K: Hydroxyprogesterone caproate. IN: Analytical profiles of drug ... C-reactive protein: a serological marker for preterm delivery? Acta Obstet Gynecol Scand. 2002 May;81(5):424-9. ... Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990 Feb;97(2):149-54. ...
Bukowski and colleagues describe an association between taking folic acid supplements and a reduction in the risk of preterm ... decrease in the risk of spontaneous preterm delivery between 20 and 28 wk (41 [0.27%] versus 4 [0.04%] spontaneous preterm ... decrease in the risk of spontaneous preterm delivery between 28 and 32 wk (58 [0.38%] versus 12 [0.18%] preterm birth, ... Long-term folate supplementation also reduced the risk of preterm delivery between 28 and 32 weeks by 50% but did not affect ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12. 348(24):2379-85. ... The ACOG does not recommend cerclage placement for women with a short cervix who do not have a history of preterm delivery, as ... Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of ... Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev. 2013. 1:CD007235. [Medline]. ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 Jun 12. 348(24):2379-85. ... 30] However, the presence of funneling does not add appreciably to prediction of the risk for preterm delivery with a short ... Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of ... Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev. 2013. 1:CD007235. [Medline]. ...
... clinicaltrials.gov The objective of the study is to determine if a weekly dose of 17P given to women with preterm rupture of ... alpha-hydroxyprogesterone caproate (17P) in the treatment of preterm delivery. Treatment with progesterone is emergin... ... preterm delivery in women with certain risk factors, notably those with a history of a prior preterm delivery and those with a ... Inflammation is a major pathway leading to preterm labor, cervical dilation & preterm delivery. 17P would seem to be like an ...
From concept to practice: the recent history of preterm delivery prevention. Part II: Subclinical infection and hormonal ... Tocolysis, use of beta-sympatomimetics for threatening preterm delivery: a critical review]. ... The use of progesterone and other progestational agents to prevent spontaneous preterm labour and preterm birth. ... Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of ...
... women with a history of spontaneous preterm birth (PTB) are recommended to receive 17-hydroxyprogesterone caproate (17-P) ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385.Google ... Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293:675-80.CrossRef ... 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964-73 Practice Bulletin No. 130.CrossRefGoogle ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-85. ... Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in ... 17 Concurrently, couples use their awareness of ovulation biomarkers to time acts of intercourse to maximize chances of ...
The control of normal birth timing in mammals andthe fundamental signals that initiate preterm birth in humans are critical ... Adams MM, Elam‐Evans LD, Wilson HG and Gilbertz DA (2000) Rates of and factors associated with recurrence of preterm delivery. ... 2006) Ethnic differences in key candidate genes for spontaneous preterm birth: TNF‐alpha and its receptors. Human Heredity 62: ... hydroxyprogesterone caproate. New England Journal of Medicine 348: 2379-2385. ...
17P reduced the rate of preterm delivery and decreased neonatal morbidity when used in women with a history of preterm delivery ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. June 12, 2003;348:2379-85. ... The rate of preterm deliveries at less than 32 weeks gestation was cut almost in half by treatment (19.6 percent of control ... Progesterone and preterm delivery-déjà vu all over again. [Editorial]. N Engl J Med. 2003;348:2453-5. ...
Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery. Am J Obstet Gynecol ... Neonatal outcome in preterm deliveries between 23 and 27 weeks gestation with and without preterm premature rupture of ... moderately preterm (32-,34 weeks) and late preterm (34-,37 weeks) birth based on the gestational age at delivery.1 This ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85.doi:10.1056/ ...
Preterm delivery rates vary widely. Unicornuate uterus has a preterm delivery rate of about 20%. This may be related to ... Preterm delivery. Patients with uterine anomalies have higher rates of preterm delivery and the greatest contributor to ... "Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate". N Engl J Med. vol. 348. 2003. pp. 2379-85. ... Preterm delivery*Uterine rupture*Growth restriction*Hypertensive disorders of pregnancy*Intrauterine fetal demise*What ...
Several large trials and systematic reviews have shown progestogens to be effective in preventing or delaying preterm birth in ... Preterm birth is a global problem, with a prevalence of 8 to 12% depending on location. ... preterm delivery, preterm delivery in maternal interest, preterm delivery in fetal interest, hospitalisation for pregnancy ... reason for risk of preterm delivery (spontaneous preterm birth yes / no and any preterm birth yes / no) ...
Learn more about Medications for Preterm Labor and Delivery at Memorial Hospital Main Risk Factors ... ... Also known as hydroxyprogesterone.. Progesterone is a hormone made by the body. It helps the uterus grow and keeps it from ... T900646/Prevention-of-preterm-labor-and-preterm-birth. Updated September 10, 2016. Accessed October 6, 2016. ... If you are having preterm labor, you may be given medication. This may include:. * Tocolytics-to delay labor . *Calcium channel ...
What is hydroxyprogesterone caproate? Meaning of hydroxyprogesterone caproate medical term. What does hydroxyprogesterone ... Looking for online definition of hydroxyprogesterone caproate in the Medical Dictionary? hydroxyprogesterone caproate ... hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy.. PREVENTION OF RECURRENT PRETERM DELIVERY BY ... hydroxyprogesterone caproate. Also found in: Wikipedia. hydroxyprogesterone caproate. (hye-drox-ee-pro-jess-te-rone kap-roe-ate ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. Meis, PJ; Klebanoff, M; Thom, E ... Should intravenous hydration be the first line of defense with threatened preterm labor? A critical review of the literature ... Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in ...
ACOG has recently updated their guidelines for preterm birth. One of the doctors on Contemporary OB/GYNs editorial board looks ... The very good news about preterm deliveries in the United States is that for the fifth year in a row, the preterm birth (PTB) ... If a patients prior delivery was a spontaneous PTB (delivery initiated by spontaneous rupture of membranes or preterm labor) ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-2385. ...
  • The objective of our study is to compare the effectiveness of weekly intramuscular injections of 17-alpha Hydroxyprogesterone Caproate, a natural metabolite of progesterone, in preventing delivery at less than 37 weeks of gestation in a population of 290 patients with twin gestations between 16 and 36 weeks of gestation compared to a placebo. (clinicaltrials.gov)
  • The frequency of delivery prior to completed 37 weeks of gestation (259 days). (clinicaltrials.gov)
  • 37 weeks of gestation due to spontaneous preterm labor or premature rupture of membranes. (drugs.com)
  • The authors screened patients for enrollment by reviewing prenatal charts of pregnancies at 15 to 20 weeks of gestation for a history of preterm delivery. (aafp.org)
  • Given the limited data, ACOG recommends restricting any consideration of the use of progesterone supplementation to women with a history of delivery before 37 weeks of gestation. (aafp.org)
  • The first phase, a case-control study, will randomly select 100 women who had a spontaneous preterm birth (before 37 weeks) and 100 women who had term birth in the Cork Ireland and Auckland New Zealand cohorts within the SCOPE study, an international consortium aimed to identify potential metabolomic predictors using biophysical data and blood samples collected at 20 weeks of gestation. (biomedcentral.com)
  • The validation phase will recruit 1150 Brazilian pregnant women from five participant centres and will collect blood and hair samples at 20 weeks of gestation to evaluate the performance of the algorithm model (sensitivity, specificity, predictive values and likelihood ratios) in predicting spontaneous preterm birth (before 34 weeks, with a secondary analysis of delivery before 37 weeks). (biomedcentral.com)
  • Pregnant women at risk for preterm birth who received betamethasone between 24 and 34 weeks of gestation were prospectively included. (biomedcentral.com)
  • An asymptomatic 32-year-old woman with a prior preterm delivery, presently pregnant with a singleton at 17 weeks of gestation, underwent transvaginal ultrasonography and was found to have a cervical length of 22 mm and dense intra-amniotic sludge. (mdedge.com)
  • She received one dose of 17α-hydroxyprogesterone caproate (17P) at 16 weeks of gestation. (mdedge.com)
  • In 2013, the FDA issued a safety alert advising against the off-label administration of magnesium sulfate injections to pregnant women for more than 5-7 days as a means of stopping preterm labor, as this agent can lead to low calcium levels and bone abnormalities in the fetus. (medscape.com)
  • Preterm SAMBA study consists of a discovery phase to identify biophysical and untargeted metabolomics from blood and hair samples associated with preterm birth, plus a validation phase to evaluate the performance of the predictive modelling. (biomedcentral.com)
  • Despite advances in medical care, racial and ethnic disparities associated with preterm birth persist. (cdc.gov)
  • The annual economic burden associated with preterm birth in the U.S. was estimated to be at least $26.2 billion, according to a 2005 estimate from the Institute of Medicine. (cdc.gov)
  • By helping the baby get as close as possible to full-term , the conditions associated with preterm birth (such as cerebral palsy , intracranial hemorrhages (brain bleeds) , infection , periventricular leukomalacia (PVL) , hypoxic-ischemic encephalopathy (HIE) , and sepsis ) can be avoided or minimized. (abclawcenters.com)
  • MLNConnects offers its Provider eNews for Dec. 17 which features updates on Collecting Data on Global Surgery as Required by MACRA Listening Session, as well as a January 2016 Average Sales Price Files. (wyomed.org)